Eiger BioPharmaceuticals Inc. (NASDAQ: EIGR) is -4.31% lower on its value in year-to-date trading and has touched a low of $4.55 and a high of $13.99 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The EIGR stock was last observed hovering at around $11.93 in the last trading session, with the day’s loss setting it -0.17% off its average median price target of $25.50 for the next 12 months. It is also 76.0% off the consensus price target high of $49.00 offered by 6 analysts, but current levels are 46.55% higher than the price target low of $22.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $11.76, the stock is 8.02% and 9.98% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.21 million and changing -1.42% at the moment leaves the stock 13.40% off its SMA200. EIGR registered -0.34% loss for a year compared to 6-month loss of 3.70%. The firm has a 50-day simple moving average (SMA 50) of $10.78 and a 200-day simple moving average (SMA200) of $10.17.
The stock witnessed a 6.72% gain in the last 1 month and extending the period to 3 months gives it a 11.47%, and is -0.51% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.34% over the week and 6.29% over the month.
Distance from 52-week low is 158.46% and -15.94% from its 52-week high.
Eiger BioPharmaceuticals Inc. (EIGR) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Eiger BioPharmaceuticals Inc. (EIGR) is a “Buy”. 6 analysts offering their recommendations for the stock have an average rating of 1.00, where 0 rate it as a Hold and 1 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Eiger BioPharmaceuticals Inc. is expected to release its quarterly report on 05/07/2021 and quarterly earnings per share for the current quarter are estimated at $0.25 with sales reaching $23.77M over the same period.The EPS is expected to grow by 19.30% this year.
Eiger BioPharmaceuticals Inc. (EIGR) Top Institutional Holders
147 institutions hold shares in Eiger BioPharmaceuticals Inc. (EIGR), with 411.85k shares held by insiders accounting for 1.27% while institutional investors hold 75.45% of the company’s shares. The shares outstanding are 29.88M, and float is at 27.71M with Short Float at 5.84%. Institutions hold 74.50% of the Float.
The top institutional shareholder in the company is 683 Capital Management LLC with over 2.62 million shares valued at $21.35 million. The investor’s holdings represent 8.06% of the EIGR Shares outstanding. As of Dec 30, 2020, the second largest holder is Blackrock Inc. with 2.38 million shares valued at $29.19 million to account for 7.30% of the shares outstanding. The other top investors are Vivo Capital, LLC which holds 1.79 million shares representing 5.51% and valued at over $14.58 million, while Ameriprise Financial, Inc. holds 4.28% of the shares totaling 1.39 million with a market value of $11.33 million.
Eiger BioPharmaceuticals Inc. (EIGR) Insider Activity
A total of 1 insider transactions have happened at Eiger BioPharmaceuticals Inc. (EIGR) in the last six months, with sales accounting for 1 and purchases happening 0 times. The most recent transaction is an insider sale by Mayer Eldon C. III, the company’s Ex VP & Chief Commerc. Officer. SEC filings show that Mayer Eldon C. III sold 1,690 shares of the company’s common stock on Jan 08 at a price of $11.68 per share for a total of $19739.0. Following the sale, the insider now owns 35810.0 shares.
Eiger BioPharmaceuticals Inc. disclosed in a document filed with the SEC on Aug 12 that Glenn Jeffrey S (Director) bought a total of 5,000 shares of the company’s common stock. The trade occurred on Aug 12 and was made at $11.42 per share for $57103.0. Following the transaction, the insider now directly holds 5000.0 shares of the EIGR stock.
Still, SEC filings show that on Aug 11, Glenn Jeffrey S (Director) acquired 5,000 shares at an average price of $11.49 for $57464.0. The insider now directly holds 71,355 shares of Eiger BioPharmaceuticals Inc. (EIGR).
Eiger BioPharmaceuticals Inc. (EIGR): Who are the competitors?
The company’s main competitors (and peers) include United Therapeutics Corporation (UTHR) that is trading 63.00% up over the past 12 months. Cytokinetics Incorporated (CYTK) is 34.11% up on the 1-year trading charts. Short interest in the company’s stock has risen 8.64% from the last report on Dec 30, 2020 to stand at a total of 1.48 million short shares sold with a short interest ratio of 3.82.